3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
12
Unknown
1
Terminated
1
No longer available
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
10
Leukemia
7
Leukemia, Myeloid, Chronic-Phase
6
Leukemia, Myeloid
2
Gastrointestinal Stromal Tumors
2
Bone Marrow Diseases
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms by Histologic Type
1
Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Blast Crisis
1
Interventions
Cyclophosphamide
48
Methotrexate
33
Cytarabine
27
fludarabine
23
fludarabine phosphate
22
Rituximab
22
Filgrastim
21
Vincristine
19
Busulfan
19
Whole-Body Irradiation
18
Mycophenolic Acid
18
Dexamethasone
18
Antilymphocyte Serum
17
Cyclosporine
16
Etoposide
15
Tacrolimus
14
Melphalan
14
Calcium Dobesilate
14
pegaspargase
12
Peripheral Blood Stem Cell Transplantation
12
Doxorubicin
12
Radiotherapy
11
Clofarabine
11
Granulocyte Colony-Stimulating Factor
10
Thiotepa
9
Bortezomib
9
thymoglobulin
8
Dasatinib
8
Asparaginase
8
plerixafor
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
nilotinib
×
Clear all
NCT00905398
2015-07-09
ALLPhi
Universidade Federal do Rio de Janeiro
Phase 1/2
Terminated
8 enrolled